Table 1 Baseline information of SLE patients (n = 45)

n

45

15

15

15

Age (years)

36.53 ± 13.54

38.00 ± 13.46

32.53 ± 11.60

39.07 ± 15.30

0.375

Female (n)

39

13

13

13

Median SLEDAI (interquartile)

12.0 (3.0, 17.0)

2.0 (0,3.0)

12.0 (10.0,20.0)

15.0 (12.0,22.0)

< 0.001

 Positive ANA (n)

45

15

15

15

–

 Positive anti-dsDNA (n)

28

8

9

11

0.516

Hypocomplementaemia (n)

24

6

7

10

0.315

 LDL-c (mmol/L)

2.85 ± 1.48

2.32 ± 0.86

3.02 ± 2.21

2.73 ± 1.33

0.478

 HDL-c (mmol/L)

1.12 ± 0.43

1.16 ± 0.39

1.37 ± 0.80

1.11 ± 0.43

0.416

 Triglycerides (mmol/L)

1.93 ± 1.20

1.53 ± 0.81

2.62 ± 1.70

1.76 ± 1.09

0.056

 Apo-A1 (g/L)

0.95 ± 0.31

1.04 ± 0.32

0.89 ± 0.27

0.98 ± 0.33

0.413

 Apo-B (g/L)

0.88 ± 0.38

0.69 ± 0.24

0.98 ± 0.43

0.89 ± 0.35

0.078

 SCr (μmol/L)

(interquartile)

59.0 (45.5104.5)

52.0 (45.0,59.0)

75.0 (50.0,153.0)

47.0 (66.0,107.0)

0.406

 eGFR(ml/min∙1.73m²)

(interquartile)

62.0 (50.0,85.8)

52.0 (45.0,58.0)

76.0 (54.0,120.0)

66.0 (58.3103.3)

0.055

 24-h urine protein (mg/L) (interquartile)

294.0 (86.0,1219.0)

170.0 (111.0,831.6)

568.0 (61.0,2126.0)

202.0 (471.0,5036.5)

0.646

 C3 (g/L)

(interquartile)

0.82 (0.59,1.03)

0.98 (0.86,1.10)

0.62 (0.46,9.00)

0.80 (0.52,1.01)

0.059

 C4 (g/L)

(interquartile)

0.16 (0.08,0.24)

0.19 (0.12,0.23)

0.10 (0.04,0.43)

0.15 (0.08,0.24)

0.372

 Hypertension (n)

15

3

7

5

0.301

 Diabetes mellitus (n)

2

0

2

0

1.000

 Hyperlipidaemia (n)

9

4

4

1

0.235

 PAH (n)

8

2

3

3

0.854

 Prednisone (n)

43

15

13

15

1.000

 Mycophenolate mofetil (n)

15

4

7

4

0.407

 Cyclophosphamide (n)

12

5

4

3

0.709

 Azathioprine (n)

6

2

3

1

0.549

 Hydrochloroquine (n)

44

15

14

15

1.000

 Cyclosporin/tacrolimus(n)

8

3

4

1

0.307

 ACE inhibitors/ARB (n)

28

8

10

10

0.685